US 12,138,256 B2
Treatment of cardiopulmonary disorders
Eva Maria Becker-Pelster, Wuppertal (DE); Hanna Tinel, Wuppertal (DE); Michael Hahn, Langenfeld (DE); Dieter Lang, Velbert (DE); Gerrit Weimann, Bergisch-Gladbach (DE); Johannes Nagelschmitz, Wuppertal (DE); Lisa Dietz, Wuppertal (DE); Soundos Saleh, Wuppertal (DE); David Jung, Wittenberg (DE); Ildiko Terebesi, Berlin (DE); Tobias Mundry, Berlin (DE); Annett Richter, Berlin (DE); Britta Olenik, Bottrop (DE); Birgit Keil, Dusseldorf (DE); Bernd Rösler, Wuppertal (DE); Peter Fey, Wuppertal (DE); Heiko Schirmer, Solingen (DE); Guido Becker, Krefeld (DE); Clemens Bothe, Leverkusen (DE); Helene Faber, Dormagen (DE); Julian Egger, Remscheid (DE); Mark Parry, Essex (GB); David Ward, Cambridgeshire (GB); and Cecile Vitre, Cambridgeshire (GB)
Assigned to Bayer Aktiengesellschaft, Leverkusen (DE); and Bayer Pharma Aktiengesellschaft, Berlin (DE)
Filed by Bayer Aktiengesellschaft, Leverkusen (DE); and Bayer Pharma Aktiengesellschaft, Berlin (DE)
Filed on Nov. 10, 2023, as Appl. No. 18/506,944.
Application 18/506,944 is a continuation of application No. PCT/EP2022/087954, filed on Dec. 28, 2022.
Claims priority of application No. 21218165 (EP), filed on Dec. 29, 2021.
Prior Publication US 2024/0148715 A1, May 9, 2024
Int. Cl. A61K 31/47 (2006.01); A61K 9/00 (2006.01); A61P 9/12 (2006.01)
CPC A61K 31/47 (2013.01) [A61K 9/0075 (2013.01); A61P 9/12 (2018.01)] 30 Claims
 
1. A method of treating a cardiopulmonary disorder in a subject comprising administering to the subject, about 240 μg to about 4000 μg of a crystalline monohydrate compound 1:

OG Complex Work Unit Chemistry
wherein, measured at 25° C. using monochromatic CuKα1 radiation of λ=1.540456 Å, 40 kV, 40 mA, the X-ray powder diffraction reflection pattern of crystalline monohydrate compound 1, expressed as ±0.2 °2θ, has at least one of the following characteristic reflections: 6.9±0.2 °2θ, 7.2±0.2 °2θ, 7.3±0.2 °2θ, 12.8±0.2 °2θ, 15.2±0.2 °2θ, 16.0±0.2 °2θ, 23.0±0.2 °2θ, 25.8±0.2 °2θ and 29.2±0.2 °2θ.